ReviewFrontiers in oncology2026
Osteosarcoma as a communication-driven disease: redefining tumor-bone signaling networks as therapeutic targets.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma (OS) is an aggressive primary bone malignancy characterized by high metastatic potential and limited therapeutic progress. Beyond genomic instability, accumulating evidence indicates that OS operates as a communication-driven disease in which dynamic intercellular signaling networks within the tumor microenvironment regulate tumor growth, immune evasion, metastatic dissemination, and therapy resistance. This review integrates current knowledge on immune cell crosstalk, extracellular vesicle-mediated signaling, soluble factors, and direct cell-cell interactions that coordinate local and systemic tumor progression. We discuss how these interconnected communication circuits shape the tumor immune microenvironment and sustain adaptive plasticity. Finally, we highlight emerging strategies aimed at disrupting pathological signaling networks, while acknowledging that many communication-targeted approaches remain at the preclinical stage or require further clinical validation. Framing OS as a communication-driven ecosystem provides a unifying conceptual model to identify novel therapeutic vulnerabilities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.